Funding and liquidity risk
The business requires continued capital raises and/or partner funding to sustain R&D.
- Scope
- Equity issuance, debt, government programs, collaborations
- Materiality
- high
Vaxart, Inc.
Vaxart, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary VAAST platform. Its pipeline includes prophylactic vaccine candidates for infectious diseases such as norovirus, coronavirus, and influenza, as well as a therapeutic HPV vaccine candidate in preclinical development.
11,2 %
6,9 %
+726,7 %
1.57
1.57
| % | |
|---|---|
| Oral vaccine platform | 0% Proprietary tablet-based vaccine technology designed to stimulate mucosal, systemic, and T-cell responses. |
| Infectious disease vaccine candidates | 0% Prophylactic vaccine programs targeting norovirus, coronavirus, and influenza. |
| Therapeutic vaccine candidates | 0% Preclinical vaccine programs aimed at HPV-related cervical cancer and dysplasia. |
| Government contract revenue | 94% Revenue from U.S. government-funded development contracts supporting vaccine programs. |
| Royalty and collaboration revenue | 6% Non-cash royalty revenue and license/collaboration income tied to partnered assets. |
Vaxart’s direct customers are primarily government agencies and contract counterparties that fund vaccine research and...
- U.S. government agenciesprimary
Fund clinical and development work through government contracts for vaccine candidates.
- Collaborative development partnersprimary
Partner with Vaxart on development, funding, and future commercialization rights.
- Future vaccine purchaserssecondary
Healthcare systems, public health programs, and distributors that would buy approved vaccines.
- Royalty payors and license counterpartiessecondary
Third parties tied to legacy partnered assets that generate royalty or license revenue.
Vaxart is headquartered in the United States and conducts its core research, development, and contracting activities...
- •Headquartered in the United States
- •Core R&D and clinical contracting are U.S.-based
- •Government contract revenue is primarily tied to U.S. agencies
- •Future commercialization may rely on ex-U.S. collaborators
- •International markets matter for eventual vaccine rollout
Vaxart’s strategy centers on advancing its oral vaccine platform through clinical development, government-funded...
01
Advance oral vaccine candidates through developmentmedium-term
Clinical progress is the main path to validating the platform and creating future product value.
02
Secure external funding and partnershipsshort-term
Government contracts and collaborations reduce funding burden and support ongoing R&D.
03
Protect and extend intellectual propertylong-term
Patent and regulatory exclusivity are central to monetizing a platform-based biotech business.
Vaxart faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, dependence on...
Clinical development and regulatory failure
Vaccine candidates must succeed in trials and obtain approval before generating product revenue.
- Scope
- Norovirus, coronavirus, influenza, HPV programs
- Materiality
- high
Third-party manufacturing and clinical service dependence
The company relies on external CROs, labs, and contract manufacturers for development work.
- Scope
- Preclinical testing, clinical trials, cGMP manufacturing
- Materiality
- high
Government contract concentration
A large share of revenue is tied to a small number of government contracts that can be stopped or reprioritized.
- Scope
- ASPR-BARDA, ATI-RRPV
- Materiality
- high
Trading liquidity and capital markets access
Delisting from Nasdaq can reduce liquidity and make future financing more difficult.
- Scope
- OTCQX quotation and state blue sky compliance
- Materiality
- medium
Government contract revenue recognition
Can create large quarter-to-quarter swings in reported revenue
Accrued research and development expenses
Affects operating expenses and liabilities
Royalty revenue and HCRP waterfall
Affects other revenue and cash conversion
Purchase commitments
Impacts liquidity analysis and balance sheet obligations
: 29.4.2026